Date: 2014-01-27
Type of information: R&D agreement
Compound: antibiotics combining beta lactamase inhibitor and carbapenem (FSI-1671 and FSI-1686)
Company: AstraZeneca (UK) FOB Synthesis (USA)
Therapeutic area: Infectious diseases
Type agreement: R&D
licensing
Action mechanism:
Disease:
Details: * On January 27, 2014, FOB Synthesis has entered into a research and development option and license agreement with AstraZeneca for the development of a novel antibiotic to treat drug-resistant bacterial infections. The treatment will potentially combine compounds from AstraZeneca’s preclinical beta lactamase inhibitor (BLI) and FOB Synthesis’ preclinical Carbapenem antibiotic programs to help break down bacteria’s resistance to carbapenems. Investigational carbapenem antibiotics developed by FOB Synthesis, FSI-1671 and FSI-1686, will be examined for the treatment of MDR Gram-negative bacterial infection. Under the terms of the agreement, AstraZeneca will develop investigational combinations of compounds through Phase I during the option phase. AstraZeneca will be solely responsible for the development and commercialization of the candidate combination compound through the option phase, and thereafter if the option is exercised by AstraZeneca. Financial details are not to be disclosed under the agreement at this time.
Financial terms:
Latest news:
